Shattuck Labs' (STTK) Neutral Rating Reaffirmed at HC Wainwright

Shattuck Labs (NASDAQ:STTK - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports.

Other research analysts also recently issued reports about the company. Needham & Company LLC restated a "hold" rating on shares of Shattuck Labs in a research note on Thursday. Citigroup downgraded Shattuck Labs from a "buy" rating to a "neutral" rating and lowered their target price for the company from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Finally, Evercore ISI raised Shattuck Labs to a "strong-buy" rating in a research note on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $8.67.

Shattuck Labs Price Performance

Shares of STTK stock opened at $1.37 on Friday. Shattuck Labs has a 1 year low of $1.07 and a 1 year high of $11.76. The firm has a fifty day moving average price of $2.13 and a 200-day moving average price of $4.34. The company has a market cap of $65.39 million, a price-to-earnings ratio of -0.74 and a beta of 1.85.

Insider Transactions at Shattuck Labs

In other news, CEO Taylor Schreiber acquired 36,500 shares of the business's stock in a transaction dated Monday, October 7th. The shares were acquired at an average cost of $1.21 per share, with a total value of $44,165.00. Following the completion of the acquisition, the chief executive officer now owns 71,002 shares of the company's stock, valued at approximately $85,912.42. This trade represents a 105.79 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in shares of Shattuck Labs by 4.8% in the first quarter. SG Americas Securities LLC now owns 39,377 shares of the company's stock worth $352,000 after acquiring an additional 1,788 shares during the period. Dimensional Fund Advisors LP raised its holdings in Shattuck Labs by 8.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company's stock worth $266,000 after purchasing an additional 5,397 shares during the period. American Century Companies Inc. boosted its position in Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company's stock worth $183,000 after purchasing an additional 9,608 shares in the last quarter. Atom Investors LP acquired a new stake in Shattuck Labs in the third quarter valued at approximately $35,000. Finally, Virtu Financial LLC purchased a new stake in shares of Shattuck Labs in the first quarter valued at approximately $113,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.